With the rapid development of precision medicine, many oncogenic driver genes have been identified in non-small cell lung cancer (NSCLC), and molecular typing is a prerequisite for the implementation of targeted therapy in NSCLC. It is of great clinical significance to select accurate, rapid and appropriate detection methods to comprehensively screen the target population for applicable targeted drugs. This product adopts the microdroplet digital PCR technology, which is patented by TargetingOne, and has the advantages of simplicity, rapidity, accuracy, universality and specificity. This product is a highquality, strictlyquality-controlled concomitant diagnostic product that can be used to assist in screening patients with non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKI), as well as to monitor lung cancer patients for early recurrence with high sensitivity and drug resistance mutations during drug administration.
